Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
B-Cell Leukemia 2 Family Proteins- B-Cell Leukemia 2 Family Proteins
- B Cell Leukemia 2 Family Proteins
- BCL2 Family Proteins
- Family Proteins, BCL2
- Proteins, BCL2 Family
- BCL2 Proteins
- Proteins, BCL2
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 6 | 6 |
| 1995 | 4 | 12 | 16 |
| 1996 | 11 | 10 | 21 |
| 1997 | 19 | 5 | 24 |
| 1998 | 21 | 10 | 31 |
| 1999 | 11 | 9 | 20 |
| 2000 | 22 | 13 | 35 |
| 2001 | 22 | 9 | 31 |
| 2002 | 26 | 19 | 45 |
| 2003 | 17 | 23 | 40 |
| 2004 | 17 | 27 | 44 |
| 2005 | 8 | 26 | 34 |
| 2006 | 9 | 15 | 24 |
| 2007 | 14 | 17 | 31 |
| 2008 | 15 | 12 | 27 |
| 2009 | 6 | 13 | 19 |
| 2010 | 10 | 19 | 29 |
| 2011 | 14 | 11 | 25 |
| 2012 | 10 | 12 | 22 |
| 2013 | 10 | 9 | 19 |
| 2014 | 4 | 11 | 15 |
| 2015 | 14 | 12 | 26 |
| 2016 | 11 | 10 | 21 |
| 2017 | 8 | 9 | 17 |
| 2018 | 4 | 8 | 12 |
| 2019 | 10 | 6 | 16 |
| 2020 | 6 | 10 | 16 |
| 2021 | 7 | 14 | 21 |
| 2022 | 2 | 17 | 19 |
| 2023 | 2 | 23 | 25 |
| 2024 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25.
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.
-
The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024 03; 262(3):255-270.
-
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death Dis. 2023 11 02; 14(11):714.
-
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
-
BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs. Cancer Res. 2023 11 01; 83(21):3501-3503.
-
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep. 2023 10 29; 13(1):18554.